TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial [0.03%]
恩夫莫单抗(TQB2618)联合派普利单抗或化疗治疗复发/转移性鼻咽癌的多中心、两队列、Ⅱ期临床试验
Cheng Xu,Si-Yang Wang,Man Nie et al.
Cheng Xu et al.
Purpose: To evaluate the efficacy and safety of dual immunotherapy blocking T-cell immunoglobulin and mucin-domain containing protein-3 (TIM-3) and programmed cell death protein-1 (PD-1) in recurrent/metastatic nasopharyn...
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial [0.03%]
brigimadlin与多柔比星治疗高级别去分化的脂肪肉瘤：来自Brightline-1随机II/III期临床试验的疗效、安全性及转化数据
Patrick Schöffski,Roberta Sanfilippo,Javier Martín-Broto et al.
Patrick Schöffski et al.
Purpose: The phase 2/3 Brightline-1 trial (NCT05218499) assessed the MDM2-p53 antagonist brigimadlin versus standard-of-care doxorubicin as first-line treatment for MDM2-amplified, locally advanced/metastatic dedifferenti...
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma [0.03%]
伊法布珠单抗在复发性胶质母细胞瘤患者中的I期和药代动力学研究
Hui K Gan,Lawrence Cher,Po-Ling Inglis et al.
Hui K Gan et al.
Purpose: To undertake a Phase 1 and Biodistribution study of the EphA3 antibody ifabotuzumab, and its zirconium labelled derivative 89Zr-ifabotuzumab, in glioblastoma patients. ...
Dihydropyrimidine dehydrogenase testing: From Pharmacogenomics to Equitable Practice [0.03%]
二氢嘧啶脱氢酶检测：从药物基因组学走向公平实践
Jacquelyne J Gaddy,Pamela L Kunz,Raghav Sundar
Jacquelyne J Gaddy
This commentary on a cohort study of patients with uncommon DPYD variants resulting in increased toxicities highlights the importance of expanding the current DPYD testing profile, the limitations of current testing, and the critical need t...
A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma [0.03%]
索托珠单抗联合仑伐替尼治疗晚期肝细胞癌患者的Ib/II期试验
Hong Jae Chon,Jeong Heo,Do Young Kim et al.
Hong Jae Chon et al.
Purpose: Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line options remain limited. Fostrox, a liver targeted prodrug,...
Felipe Galvez-Cancino,Eileen E Parkes,David R Withers et al.
Felipe Galvez-Cancino et al.
Next generation anti-CTLA-4 antibodies have been designed and tested to improve the efficacy and therapeutic index by leveraging enhanced Fc-mediated effector function with conditional tumour-restricted activation. The goal is to achieve ro...
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy [0.03%]
用于头颈部转移性鳞状细胞癌的静脉注射溶瘤腺病毒VCN-01和durvalumab一期临床试验（免疫疗法耐药）
Maria Jove,Irene Braña,Marc Oliva et al.
Maria Jove et al.
Purpose: VCN-01 is a hyaluronidase-expressing oncolytic adenovirus that increases immune checkpoint antibody tumor uptake in mice. VCN-01 was evaluated with durvalumab in recurrent/metastatic head and neck squamous cell c...
Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft Tissue Sarcoma [0.03%]
利用个性化的结构变异检测ctDNA以预测局灶性软组织肉瘤的复发
Changsu L Park,Elizabeth G Demicco,Karen Howarth et al.
Changsu L Park et al.
Background: Soft tissue sarcoma (STS) is a heterogeneous disease characterized by high prevalence of structural variants (SV). Despite surgery and radiation, ~50% of localized STS recur; the role of adjuvant systemic ther...
Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications [0.03%]
胰腺癌中KRAS突变和MTAP丢失汇合的基因组景观及其临床意义
Camila Braganca Xavier,Pooja A Shah,Daria Yakimova et al.
Camila Braganca Xavier et al.
Purpose: Comprehensive genomic profiling has prognostic and predictive value for patients with pancreatic adenocarcinoma. Experimental design: ...
Polygenic risk scores for prediction of immune checkpoint inhibitor thyroid toxicity in diverse populations [0.03%]
用于预测免疫检查点抑制剂在不同人群中的甲状腺毒性的多基因风险评分
Lars G Fritsche,Luke M Higgins,Matthew Schipper et al.
Lars G Fritsche et al.
Background: Immune checkpoint inhibitor (ICI)-induced thyroiditis is a common immune-related adverse event (irAE) linked to improved survival. Polygenic risk scores (PRSs) for autoimmune hypothyroidism predict thyroid irA...